Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)‘s stock had its “buy” rating reiterated by analysts at Royal Bank Of Canada in a research report issued to clients and investors on Friday. They currently have a $54.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 12.13% from the stock’s previous close.

Several other research firms have also issued reports on ENTA. Robert W. Baird lifted their price target on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, August 8th. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 11th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $38.00 price target (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday, August 9th. Finally, JMP Securities lifted their price target on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Enanta Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $45.25.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) opened at 48.16 on Friday. The company has a 50 day moving average price of $45.64 and a 200 day moving average price of $37.42. Enanta Pharmaceuticals has a 1-year low of $22.17 and a 1-year high of $49.50. The stock’s market cap is $919.37 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. During the same period in the previous year, the company earned ($0.06) earnings per share. The business’s revenue for the quarter was down 46.3% on a year-over-year basis. On average, equities analysts anticipate that Enanta Pharmaceuticals will post $1.14 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Enanta Pharmaceuticals, Inc. (ENTA) Given Buy Rating at Royal Bank Of Canada” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/21/enanta-pharmaceuticals-inc-enta-given-buy-rating-at-royal-bank-of-canada.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Mason Street Advisors LLC grew its holdings in shares of Enanta Pharmaceuticals by 7.0% during the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 212 shares during the last quarter. GAM Holding AG purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at $108,000. Municipal Employees Retirement System of Michigan grew its holdings in shares of Enanta Pharmaceuticals by 3.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 110 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Enanta Pharmaceuticals by 5.8% during the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 237 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Enanta Pharmaceuticals by 62.9% during the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,702 shares during the last quarter. 66.06% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.